Welcome to our dedicated page for Talphera news (Ticker: tlph), a resource for investors and traders seeking the latest updates and insights on Talphera stock.
Talphera Inc. (TLPH) is a specialty pharmaceutical innovator developing therapies for critical care environments, with a focus on nafamostat-based anticoagulants and pre-filled syringe technologies. This page aggregates all official announcements, clinical trial milestones, and regulatory developments related to the company's pursuit of safer treatment protocols in high-risk medical settings.
Investors and healthcare professionals will find timely updates on key initiatives including the NEPHRO study evaluating Niyad™ for extracorporeal circuits, progress toward Breakthrough Device designation, and strategic partnerships advancing pre-filled syringe candidates. The curated newsfeed serves as a comprehensive resource for tracking pipeline advancements and evidence-based therapeutic innovations.
Content spans quarterly financial results, FDA correspondence, peer-reviewed research publications, and manufacturing updates. All materials are sourced directly from company disclosures to ensure compliance with financial reporting standards.
Bookmark this page for structured access to Talphera's evolving clinical strategy and pharmaceutical development progress. Cross-reference announcements with SEC filings via provided documentation links for complete context.
Talphera (NASDAQ: TLPH) announced key developments in its Q4 and full year 2024 financial results. The FDA approved reducing the NEPHRO CRRT study patient count from 166 to 70, maintaining 90% power for the primary endpoint. The company secured potential financing of up to $14.8 million through private placement.
Financial highlights include $8.9 million in cash and cash equivalents as of December 31, 2024. Q4 2024 saw reduced operating expenses with combined R&D and SG&A of $3.0 million, down from $4.6 million in Q4 2023. Net loss improved to $1.9 million ($0.07 per share) compared to $4.5 million ($0.25 per share) in Q4 2023.
The company projects 2025 cash operating expenses between $18-19 million, covering the NEPHRO CRRT registration trial completion expected by year-end 2025.
Talphera (NASDAQ: TLPH) announced two significant developments: FDA approval to reduce the NEPHRO CRRT study size from 166 to 70 patients, and a private placement financing of up to $14.8 million. The study reduction maintains a 90% powered primary endpoint, with 6 patients already enrolled and completion targeted for end of 2025.
The private placement, led by Nantahala Capital and Rosalind Advisors, is structured in three tranches: $4.925 million initial closing (April 2, 2025), and two additional $4.925 million tranches tied to patient enrollment milestones of 17 and 35 patients respectively. Each milestone requires a minimum stock price of $0.7325 for five consecutive days.
With $8.9 million in cash as of December 31, 2024, plus the potential $14.8 million financing, Talphera expects sufficient capital through the NEPHRO CRRT study completion. The company anticipates submitting PMA early next year with potential approval in second half of 2026.
Talphera (NASDAQ: TLPH) has announced it will release its fourth quarter and full-year 2024 financial results after market close on Monday, March 31, 2025. The specialty pharmaceutical company, focused on developing innovative therapies for medically supervised settings, will host a live webcast and conference call at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Standard.
The webcast will feature a slide presentation and can be accessed through the company's website at www.talphera.com in the Investors/News & Events/Upcoming Events section. A replay will be available for 90 days following the event. Investors can join the conference call by dialing 1-800-836-8184 (North America) or 1-646-357-8785 (international) using conference ID 11814.
Talphera (NASDAQ: TLPH) has announced significant developments in its NEPHRO CRRT clinical study following a meeting with the FDA. The agency has agreed to review a Prior Approval Supplement (PAS) for reducing the number of patients in the study, with the submission expected within the week. The FDA's review process will take up to 30 days.
Additionally, the FDA approved two protocol changes that will expedite enrollment: allowing the inclusion of patients on continuous renal replacement therapy (CRRT) beyond 48 hours and permitting heparin-tolerant patients at certain institutions. These changes will be implemented through a five-day protocol amendment notice, requiring no additional FDA review.
The company aims to complete the NEPHRO CRRT study by year-end, with nafamostat being developed as an alternative anticoagulant for CRRT patients under breakthrough designation status.
Talphera (TLPH) reported Q3 2024 financial results, highlighting progress in its NEPHRO CRRT study with five active sites screening patients and two additional sites expected to begin in Q4. The company ended Q3 with $11.1 million in cash and investments. Financial results showed a net loss of $3.4 million ($0.13 per share), compared to $1.4 million loss in Q3 2023. Combined R&D and SG&A expenses increased to $3.7 million from $3.4 million year-over-year, primarily due to NEPHRO study costs. The study will enroll 166 patients across up to 14 U.S. clinical sites, with the primary endpoint measured at 24 hours.
Talphera will release its third quarter 2024 financial results on November 13, 2024 after market close. The company will also host a live webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a business update. The webcast can be accessed through the Investors section of Talphera's website and will include a slide presentation. A replay will be available for 90 days post-event. Investors can join the conference call by dialing 1-800-836-8184 (North America) or 1-646-357-8785 (international) using the conference ID 89949.
Talphera (Nasdaq: TLPH), a specialty pharmaceutical company, has announced its participation in the 2024 Maxim Healthcare Virtual Summit. The company's management will engage in a fireside chat and be available for one-on-one meetings with registered investors during the event, which is scheduled for October 15-17, 2024.
Key details of Talphera's participation include:
- Event: 2024 Maxim Healthcare Virtual Summit
- Date: October 16, 2024
- Time: 3:00 PM ET / 12:00 Noon PT
Talphera focuses on developing and commercializing innovative therapies for use in medically supervised settings. Investors and interested parties can access the fireside chat through the provided webcast link.
Talphera (Nasdaq: TLPH), a specialty pharmaceutical company, announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event is scheduled for September 9-11, 2024, at the Lotte New York Palace Hotel in New York City. Talphera's management will be available for one-on-one meetings during the conference.
The company's presentation will be accessible on-demand starting September 9 at 7:00 AM ET. Interested parties can view the presentation through a provided link or by visiting the Investors section of Talphera's website at www.talphera.com. The webcast link can be found in the Investors/News & Events/Upcoming Events section.
Talphera (Nasdaq: TLPH) has announced the enrollment of the first patient in its NEPHRO CRRT registrational trial, evaluating nafamostat for anticoagulation in extracorporeal circuits. The study will involve 166 patients across 14 clinical sites in the United States. The primary endpoint is the mean post-filter activated clotting time over the first 24 hours, comparing nafamostat to placebo.
Dr. Stuart Goldstein, a renowned nephrologist, enrolled the first patient. Nafamostat has been a standard of care in Japan and South Korea for over 30 years, and Talphera aims to make it available in the U.S. market if approved. The company views this as a significant milestone in addressing the limitations of current anticoagulation options for continuous renal replacement therapy (CRRT).
Talphera (Nasdaq: TLPH) announced its Q2 2024 financial results and provided a corporate update. Key highlights include:
1. Initiation of patient screening at multiple clinical sites for the NEPHRO CRRT registrational study, which will assess nafamostat's safety and effectiveness in 166 patients across up to 14 clinical sites.
2. Cash and investments of $14.0 million as of June 30, 2024.
3. Q2 2024 financial results: Combined R&D and SG&A expenses of $4.3 million, net loss from continuing operations of $3.8 million, and net loss attributable to common shareholders of $3.8 million ($0.15 per share).
4. Appointment of Dr. Shakil Aslam as Chief Development Officer, who will succeed Dr. Palmer as Chief Medical Officer upon her retirement in October.
FAQ
What is the current stock price of Talphera (tlph)?
What is the market cap of Talphera (tlph)?
